Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial

Published:2022-06-17 Issue:3 Volume:11 Page:1269-1283
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Yu Tingmin,He Li,Yang Xiaosu,Zhou Jiying,Luo Guogang,Wang Hebo,Zhao Hongru,Hu Quan,Ji Fei,Yu Shengyuan^ORCID

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-022-00369-1.pdf

Reference26 articles.

1. Headache Classification Committee of the International Headache Society (IHS). ICHD-3. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

2. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava, Lifting the Burden: The Global Campaign Against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.

3. Yu S, Liu R, Zhao G, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–91.

4. Yao C, Wang Y, Wang L, et al. Burden of headache disorders in China, 1990–2017: findings from the Global Burden of Disease Study 2017. J Headache Pain. 2019;20(1):102.

5. Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials;The Journal of Headache and Pain;2024-02-05